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Abstract Ciliary neurotrophic factor (CNTF) is a molecule 
which has profound effects on various neural cell types. In the 
central nervous system, expression of CNTF-mRNA is highly 
concentrated in olfactory bulb. In the present study, we examined 
the regulatory mechanism of CNTF-mRNA expression in cul- 
tured astrocytes from newborn rat brain. Cultured astrocytes 
from new born rat brain expressed CNTF-mRNA at levels com- 
parable to the level in olfactory bulb in vivo. Treatment of the 
astrocytes with forskolin, an activator of adenylyl cyclase, led to 
a decrease of CNTF-mRNA level. The effect of forskolin was 
mimicked by cAMP-linked agonists, such as VIP, PACAP, iso- 
proterenol and dopamine. Cycloheximide, an inhibitor of protein 
synthesis, did not abolish the forskolin-induced decrease of 
CNTF-mRNA. Measurement of the half-life of CNTF-mRNA in 
the presence of actinomycin D, an inhibitor of transcription, indi- 
cated that the degradation of CNTF-mRNA is not destabilized 
by the forskolin-treatment. These data taken together suggest 
that the cAMP-induced suppression of CNTF-mRNA is mainly 
caused by the inhibition of CNTF gene transcription. 
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I. Introduction 
CNTF was originally identified as a target derived neurotro- 
phic molecule supporting the survival of parasympathetic cili- 
ary neurons [1,2]. Now it became aware that CNTF  exerts a 
broad spectrum of biological actions on various types of neu- 
ronal cells as well as on glial cells in culture [3-5]. The expres- 
sion of CNTF in the CNS is highly concentrated in olfactory 
bulb suggesting that CNTF has unique functions in this region 
of brain [2,6]. To elucidate the function of CNTF in the olfac- 
tory system, it is important o know how the expression of 
CNTF is regulated in situations linked to the physiological 
activities of the olfactory system. Using immunohistochemical 
technique, it is shown that, within olfactory bulb, the expres- 
sion of CNTF is localized to subpopulation of astrocytes [6]. 
In the present study, as a first step to investigate the function 
of CNTF in the olfactory system, we analyzed the regulatory 
mechanism of the CNTF  expression in the cultured astrocytes 
prepared from new born rat olfactory bulb. The results indi- 
cated that the astrocytes from olfactory bulb expressed CNTF-  
mRNA at high level comparable to that in olfactory bulb in 
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Abbreviations." CNTF, ciliary neurotrophic factor; NGF, nerve growth 
factor; VIP, vasoactive intestinal polypeptide; PACAP, pituitary ade- 
nylyl cyclase-activating polypeptide; IBMX, 3-isobutyl-l-methylxan- 
thine. 
vivo. Forskolin, an activator of adenylyl cyclase, as well as 
cAMP-linked agonists suppressed the expression of CNTF-  
mRNA in the olfactory bulb astrocytes. The mechanism and 
the physiological implications of the forskolin-induced suppres- 
sion of CNTF-mRNA level are discussed. 
2. Materials and methods 
2.1. Materials 
Dulbecco's modified Eagle's medium (DMEM), poly-L-ornithine, 
ionomycin, dideoxyforskolin, 3 4-dihydroxyphenethylamine (dopam- 
ine) were purchased from Sigma (St. Louis), forskolin, actinomycin D,
cycloheximide, 3-isobutyl-l-methylxanthine (IBMX), dl-isoproterenol 
were from Wako Pure Chemical (Tokyo), vasoactive intestinal polypep- 
tide (VIP), carnosine, and substance P were from Peptide Institute 
(Osaka), fetal calf serum was from Gibco (New York), penicillin and 
streptomycin were from Meiji Seika (Tokyo). Pituitary adenylyl 
cyclase-activating polypeptides (PACAP-27 and PACAP-38) were gen- 
erous gift from Dr. Watanabe, T. of Takeda Pharmaceutical Industries 
(Osaka). Plasmid (pBluescript SK(-)) containing rat CNTF-cDNA [2] 
used for making sense and antisense cRNA was kindly provided by Dr. 
P. Caroll (Martinsried, FRG). 
2.2. Cell culture 
Astrocytes were prepared essentially as described previously [7]. Ol- 
factory bulbs and cerebral cortices were dissected from 2-day-old Wis- 
tar rats and treated with 0.25% trypsin in DMEM for 20 min. After 
trituration with pipette, dissociated cells were collected by centrifuga- 
tion, resuspended with DMEM supplemented with 10% fetal calf serum 
and antibiotics (50 U/ml penicillin and 100 ¢tg/ml streptomycin) and 
plated on 35 mm culture dishes (approximately 1 x l0  6 cells/dish) which 
were precoated with 100 /.tg/ml poly-L-ornithine. The medium was 
changed on the day following plating and thereafter every third day. 
Cells were grown for 7-10 days before stimulation with various com- 
pounds. 
2.3. RNA analysis 
Total RNA was prepared from the cells according to the method of 
Chomczynski and Sacchi [8]. The extraction buffer contained 20 pg of 
0.6-kb long CNTF standard RNA to evaluate the recovery of RNA. 
RNA samples were glyoxylated, electrophoresed through a 1.5% aga- 
rose gel, and then transferred toa nylon membrane (Hybond-N, Amer- 
sham). Following transfer, membranes were fixed by UV irradiation. 
Membranes were prehybridized, and hybridized with 32p-labeled anti- 
sense CNTF-cRNA probe (0.6 kb) at 65°C in 50% formamide. Mem- 
branes were washed and exposed to Kodak X-OMAT AR. The radio- 
activity bound to CNTF-mRNA was quantified with Bio-image ana- 
lyzer (Fuji Photo Film) and corrected for recovery of RNA. 
3. Results 
3.1. Expression of CNTF-mRNA in rat brain and cultured 
astrocytes 
Quantitative Northern blot analysis was performed to evalu- 
ate the expressions of CNTF-mRNA in different regions of 
adult rat brain and cultured astrocytes (Fig. 1). Olfactory bulb 
expressed the highest level of CNTF-mRNA in brain, while the 
levels of CNTF-mRNA in other brain regions uch as cerebrum 
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Fig. 1. Northern blot analysis of CNTF-mRNA in adult rat brain and 
cultured astrocytes. The positions of CNTF-mRNA (1.2 kb) and 28s 
ribosomal RNA were indicated by arrows. Lane 1, cerebral cortex; lane 
2, midbrain; lane 3, cerebellum; lane 4, olfactory bulb; lane 5, cultured 
olfactory bulb astrocytes; lane 6, cultured cerebral cortex astrocytes. 
Each lane contained 10¢tg of total RNA. Even recovery of loaded RNA 
on the membrane was confirmed by staining of ribosomal RNA with 
methylene blue. 
cortex, mid brain and cerebellum were very low. This result 
confirms the observation by St6ckli et al. [6] that olfactory bulb 
expresses the highest level of CNTF-mRNA in central nervous 
system. Cells were dissociated from newborn rat olfactory bulb 
and cerebral cortex and were maintained inDMEM containing 
10% fetal calf serum. During the culture period for one week, 
the confluent monolayer of flat cells was obtained. Most of 
neuron-like cells were eliminated during this period by massive 
proliferation of the flat cells. Immunostaining with anti-GFAP 
antibody revealed that the monolayer of flat cells obtained from 
both olfactory bulb and cerebral cortex consisted of Type 
1-astrocytes with purity of >95%. The cultured olfactory bulb 
astrocytes expressed a relatively high level of CNTF-mRNA 
(approximately 1 pg/pg total RNA), which was 7.2-fold higher 
than the level in adult rat olfactory bulb in vivo (Fig. 1). Inter- 
estingly, astrocytes obtained from cerebral cortex also ex- 
pressed the CNTF-mRNA at the level comparable to that ex- 
pressed by olfactory bulb astrocytes. 
3.2. Suppression of CNTF-mRNA in cultured astrocytes by 
cAMP producing agents 
cAMP has been shown to mediate the increase in NGF- 
mRNA levels in cultured astrocytes and Schwann cells [9-11]. 
Contrary, CNTF-mRNA in the cultured astrocytes from both 
olfactory bulb and cerebral cortex was abolished by treatment 
with forskolin, an activator of adenylyl cyclase. In cultured 
olfactory bulb astrocytes CNTF-mRNA was decreased to less 
than 20% of the original evel with 10 ¢tM forskolin at 9 h of 
the treatment and half-maximal concentration f forskolin was 
approximately 0.3 tiM (data not shown). Analysis of the time 
course of the forskolin-suppression of CNTF-mRNA indicated 
that the level of CNTF-mRNA was decreased by 50% at 4.7 h 
after addition of 20 tiM forskolin and to less than 20% of the 
original evel at 9 h of the treatment (Fig. 4). 3-Isobutyl-1- 
methylxanthine (IBMX), an inhibitor of phosphodiesterase, 
mimicked the effect of forskolin on the suppression of CNTF- 
mRNA at concentrations above 10 ¢tM. Thus, CNTF-mRNA 
was decreased to46.5% of the original level at 9 h after addition 
of 100 pM IBMX (Table 1). Alternatively, dideoxyforskolin, an
analog of forskolin which has no ability to activate adenylyl 
cyclase, but shares other cellular effects with forskolin, did not 
affect the levels of CNTF-mRNA in olfactory bulb astrocytes 
(Table 1). These results uggest that the accumulation f intra- 
cellular cAMP led to the abolishment of CNTF-mRNA in the 
cultured astrocytes from olfactory bulb and cerebral cortex. 
3.3. EJ]ects of cAMP-linked agonists on the CNTF-mRNA 
levels in cultured astrocytes 
Variety of receptors for transmitters and neuropeptides 
which are linked to adenylyl cyclase are known to be expressed 
in brain astrocytes [12-16]. Therefore, we attempted to identify 
major cAMP-linked agonists capable to down-regulate CNTF- 
mRNA in olfactory bulb astrocytes. As a result, agonists for 
dopamine, fl-adrenergic, vasoactive intestinal polypeptide 
(VIP) and pituitary adenylyl cyclase-activating polypeptide 
(PACAP) receptors were effective in decreasing the CNTF- 
mRNA levels (Table 1, Fig. 2). Dopamine and isoproterenol, 
a fl-adrenergic agonist, showed modest effects. Thus, the 
CNTF-mRNA level was decreased to 72% and 75% of the 
original level by 9-h treatments with 100 pM isoproterenol and 
100/~M dopamine, respectively. Calcitonin gene-related pep- 
tide (CGRP), known as an adenylyl cyclase-linked neuropep- 
tide [17], did not affect he suppression ofCNTF-mRNA in the 
olfactory bulb astrocytes. 
VIP and PACAP exerted the prominent effects on the 
CNTF-mRNA levels. That is, in the cultured astrocytes from 
olfactory bulb, CNTF-mRNA level was decreased to 66.6% of 
the original evel by a 9 h-treatment with 100 nM VIP while it 
was decreased to 49 and 66% at 9-h treatments with 100 nM 
PACAP27 and PACAP38, respectively (Fig. 2A). Olfactory 
bulb astrocytes responded to PACAP27, PACAP38 and VIP 
with approximate ECs0 value of 0.1, 0.1 and 10 nM, respec- 
tively. Similarly, in the cultured astrocytes from cerebral cortex, 
the CNTF-mRNA level was decreased to 25.4% of original 
level at 9 h after the addition of 100 nM VIP while it was 
decreased to 14.3 and 22.5% at 9-h treatments with 100 nM 
PACAP27 and PACAP38, respectively (Fig. 2B). Cerebral 
Table l 
Effects of various compounds on the CNTF-mRNA levels 
Compounds Concentration CNTF-mRNA Range 
None 100.0 
FK* 20 pM 19.3 + 4.2 
DFK* 20 ,uM 96.6 + 10.0 
IBMX* 100/tM 46.5 + 1.7 
Dopamine 100 pM 74.7 + 8.5 
Isoproterenol 100 pM 72.4 + 0.2 
CGRP 50 nM 99.1 + 2.9 
VIP 100 nM 66.6 _+ 2.3 
PACAP38 100 nM 65.9 _+ 4.9 
PACAP27 100 nM 49.0 + 9.2 
Substance P 100/IM 95.6 + 5.5 
Carnosine 100 ¢tM 106.3 _+ 0.3 
Ionomycin 0.1 mg/ml 100.1 + 0.4 
Cultured astrocytes from olfactory bulb were incubated with the neuro- 
transmitters and neuropeptides at the indicated concentrations for9 h. 
Each data represents the mean and range of duplicate samples except 
for compounds with asterisk where data represents the mean + S.D. 
(n = 4). FK, forskolin; DFK, dideoxyforskolin. 
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Fig. 2. Dose-dependence of neuropeptides on CNTF-mRNA levels. 
Cultured astrocytes from olfactory bulb (A) or cerebral cortex (B) were 
incubated with indicated concentrations of neuropeptides for9 h: VIP 
(El), PACAP 27 (e), PACAP 38 (©). Each data point represents the 
mean and range of duplicate samples. 
cortex astrocytes responded to all the three peptides with an 
approximate ECs0 value of 0.1 nM. Analysis of the time course 
of the changes in the CNTF-mRNA levels revealed that the 
effects of neuropeptides were transient (Fig. 3). That is, the 
CNTF-mRNA level was decreased to the minimum at 9 h after 
addition of 10 nM VIP, PACAP27 or PACAP38, but, after that 
time point, the CNTF-mRNA levels began to recover and the 
original evel was almost regained at 24 h. 
On the other hand, a treatment of the astrocytes with 0.1 
mg/ml ionomycin, a Ca-ionophore, did not change the CNTF- 
mRNA level (Table 1). Similarly, Substance P, a neuropeptide 
known to be coupled to phosphatidyl inositol turnover and 
mobilization of intracellular Ca 2÷ [18], did not affect he CNTF- 
mRNA level in the cultured astrocytes. Incidentally, carnosine, 
the putative transmitter of olfactory neuron [19,20], did not 
change the CNTF-mRNA level in olfactory bulb astrocytes. 
3.4. Regulatory mechanism of  CNTF-mRNA expression by 
cAMP in olfactory bulb astrocytes 
We examined whether de novo protein synthesis is required 
for the forskolin-induced process. Treatment of the olfactory 
bulb astrocytes with cycloheximide, an inhibitor of protein syn- 
thesis, slightly increased the CNTF-mRNA level (120% of the 
original evel) up to 12 h of the treatment (Fig. 4A). Thereafter, 
the CNTF-mRNA level began to decrease slowly. When cyclo- 
heximide was added in combination with forskolin, the CNTF- 
mRNA level decreased with a time course very similar to the 
case where forskolin alone was added. Thus, the forskolin- 
induced suppression of CNTF-mRNA was not canceled by the 
cycloheximide-treatment. Therefore, it is strongly suggested 
that the forskolin-induced suppression of CNTF-mRNA was 
not resulted from de novo protein synthesis. 
There are two possibilities for forskolin to suppress the ex- 
pression of CNTF gene at mRNA level. The first possibility is 
the destabilization f the CNTF-mRNA and the other possibil- 
ity is the inhibition of CNTF gene transcription. First, we 
examined whether the destabilization f CNTF-mRNA partic- 
ipates in the forskolin-induced suppression of CNTF-mRNA 
in the olfactory bulb astrocytes. The half-life of the CNTF- 
mRNA was measured by following the time course of decay of 
CNTF-mRNA after addition of actinomycin D, an inhibitor of 
transcription, to the cells treated with or without forskolin. As 
shown in Fig. 4B, addition of actinomycin D to the untreated 
astrocytes induced the decay of CNTF-mRNA with a half-life 
(t~/2) of 7 h. This half-life corresponds to the native stability of 
CNTF-mRNA. But, in the presence of actinomycin D, fors- 
kolin did not accelerate the decay of CNTF-mRNA. Thus, the 
half-life became rather slightly longer (tl/2 -- 10 h) than that of 
the cells treated with actinomycin D alone. Since forskolin 
abolishes CNTF-mRNA even in the presence of cycloheximide 
and forskolin does not promote degradation of CNTF-mRNA 
in the presence of actinomycin D, it is suggested that forskolin 
decreases the level of CNTF-mRNA via inhibition of transcrip- 
tion of CNTF gene in a de novo protein synthesis independent 
manner as a major pathway. Further confirmation of the inhi- 
bition of CNTF gene transcription by forskolin and its contri- 
bution to the forskolin-induced suppression of CNTF-mRNA 
should await the nuclear un-off assay. Alternatively, the slight 
acceleration of the degradation of CNTF-mRNA by forskolin 
alone (tl/2 = 4.7 h) and its cancellation by actinomycin D sug- 
gest that forskolin destabilized the CNTF-mRNA in a protein 
synthesis dependent manner to contribute partly to the fors- 
kolin-induced suppression of CNTF-mRNA. 
4. Discuss ion 
The goal of the present study was to obtain information on 
the mechanism involved in the regulation of CNTF expression 
in the cultured brain astrocytes as a basis for understanding of
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Fig. 3. Time courses of changes in CNTF-mRNA levels induced by 
neuropeptides, olfactory bulb astrocytes were treated with 10 nM of 
neuropeptides for the indicated time: VIP (tz), PACAP 27 (t), PACAP 
38 (©). Each data point represents he mean and range of duplicate 
samples. 
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Fig. 4. Effects of cycloheximide and actinomycin D on the forskolin- 
induced suppression of CNTF-mRNA. (A) cultured astrocytes from 
olfactory bulb were pretreated with 10 mg/ml cycloheximide for 0.5 h. 
Then, the astrocytes were further incubated with cycloheximide alone 
(©) or with 20/IM forskolin (o) for the indicated time. Time course of 
change in the CNTF-mRNA levels of the cells treated with forskolin 
alone is also indicated ([]). (B) olfactory bulb astrocytes were pretreated 
with 10/lg/ml actinomycin D for 0.5 h. Then, the astrocytes were 
further incubated with actinomycin D alone (e) or with 20,uM forskolin 
(©) for the indicated time. Time course of changes in CNTF-mRNA 
levels of the astrocytes treated with forskolin alone is also indicated (D). 
Each data point represents he mean and range of duplicate samples. 
the in vivo role of CNTF in the olfactory system. CNTF has 
been shown to be expressed in glial cells of both central and 
peripheral nervous ystem such as astrocytes and Schwann cells 
[6,21]. We also confirmed the high level of CNTF-mRNA ex- 
pression in the cultured astrocytes prepared from olfactory 
bulb and cerebral cortex. Using cultured astrocytes which 
mimic reactive astrocytes in vivo [22], we first looked for extra- 
and intra-cellular signals regulating CNTF-mRNA. 
The high level of CNTF-mRNA expression i cultured astro- 
cytes was suppressed by accumulation of cAME Among vari- 
ous cAMP-linked agonists, PACAPs and VIP were the most 
prominent suppresser of the CNTF-mRNA in the cultured 
astrocytes. Recently it was reported that Type I PACAP recep- 
tor which preferentially utilizes PACAPs over VIP is expressed 
in limited regions in the brain including glomerular layer of 
olfactory bulb [23]. Two types of VIP receptors (VIP1 and 
VIP2) which bind PACAPs and VIP with the same affinity are 
also expressed in olfactory bulb [24,25]. On the other hand, in 
cerebral cortex, the expression of only the VIP1 receptor is 
reported [26]. In the present study, PACAPs were 100 times 
more effective than VIP on suppressing the CNTF-mRNA in 
the cultured astrocytes from olfactory bulb, while PACAPs and 
VIP were equally effective in the cultured astrocytes from cere- 
bral cortex. Hence, our results suggest that PACAPs and VIP 
activate Type I PACAP receptor and VIP1 receptor to suppress 
CNTF-mRNA in the cultured astrocytes from olfactory bulb 
and cerebral cortex, respectively. It is important o clarify 
whether these neuropeptides and their receptors are involved 
in the regulation of CNTF expression i  vivo. Especially, it is 
interesting to examine whether changes in the levels of these 
neuropeptides in brain during development and injury correlate 
with those of CNTF expression. 
Intracellular mechanism in which activation of adenylyl 
cyclase leads to the suppression of CNTF-mRNA levels seems 
to be complex. It is generally accepted that cAMP exerts its 
cellular effects mostly via activation of cAMP-dependent pro- 
tein kinase (PKA) [27] . However, elucidation of the roles of 
PKA in the suppression of CNTF-mRNA is ambiguous. Treat- 
ment of the cultured astrocytes with H-89, a selective inhibitor 
of PKA [28], as well as H-85, an analog of H-89 which is devoid 
of the action on PKA [28], did not reverse the forskolin-induced 
suppression of CNTF-mRNA (data not shown). Furthermore, 
H-89 and H-85 themselves decreased the CNTF-mRNA levels 
to 30.3 and 61.5% of original level, respectively with the 
9 h-incubation. We also found that other protein kinase inhib- 
itors such as H-7 and staurosporine also decreased the CNTF- 
mRNA levels (data not shown). Complex cascades of protein 
phosphorylation seem to be involved in the cAMP-induced 
up-regulation of CNTF-mRNA expression as well as in its 
basal expression. 
The transient nature of the effect of VIP and PACAPs might 
have resulted from desensitization processes between activa- 
tions of the receptor and adenylyl cyclase while forskolin acti- 
vated adenylyl cyclase persistently to induce long lasting sup- 
pression of CNTF-mRNA level. Alternatively, neuropeptides 
added to the culture medium might have been degraded by 
proteases on the surface of astrocytes. Interestingly, removal 
of forskolin from the culture medium of astrocytes also quickly 
recovered the expression of CNTF-mRNA indicating the re- 
versible nature of the action of forskolin (data not shown). 
Hence, it is suggested that persistent activation of adenylyl 
cyclase is required for the suppression of CNTF-mRNA ex- 
pression. 
Our experiments suggest hat elevated cAMP induces the 
inhibition of transcription of CNTF gene as a major pathway 
to quench the CNTF-mRNA level. However, it is also sug- 
gested that the promotion of degradation of CNTF-mRNA by 
forskolin contributes subsidiary. Since, stably and strongly ex- 
pressed CNTF-mRNA has longer half life (t~/2 = 7 h) compared 
with that of NGF-mRNA (t~/2 = 0.67 h [11]), it is reasonable to 
utilize the mRNA destabilizing machinery in addition to tran- 
scriptional inhibition to quench the CNTF-mRNA expression 
rapidly in physiological events. The effects of cycloheximide on 
the CNTF-mRNA level suggested that the inhibition of CNTF 
transcription did not require de novo protein synthesis and was 
evoked by post translational modification of constitutively ex- 
pressed transcription factor. Future analysis of the sequence 
elements on the promoter region of CNTF gene responsible for 
the action of cAMP would reveal the identity of transcription 
factors regulating CNTF gene expression. 
Regulatory mechanisms of CNTF-mRNA expression i  the 
CNS and PNS in vivo are largely unknown. In the peripheral 
nervous ystem, after transection or crush of the sciatic nerve, 
CNTF immunoreactivity and CNTF-mRNA levels expressed 
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in Schwann cells fall dramatically while expressions of NGF 
immunoreactivity and NGF-mRNA in Schwann cells are in- 
duced dramatically [29 32]. Expression of CNTF is regained 
when the nerve is regenerated [31,33]. Therefore, CNTF is 
thought o be atrophic factor for the intact sciatic nerve and 
may function also as a lesion factor to exert acute trophic 
effects when released from Schwann cells in response to injury, 
while NGF released from Schwann cells is thought o promote 
the subsequent erve regeneration. 
But, the regulatory mechanisms of the CNTF expression i  
CNS and PNS may be different. Recently it is reported that 
after injury to cerebral cortex and hipocampus where basal 
level of CNTF-mRNA is very low, astrocytes are activated to 
proliferate to fill in the lesioned sites and increase the expres- 
sion of CNTF-mRNA concomitantly with expression of NGF- 
mRNA [34]. Hence, it is suggested that astrocytes in general 
express very low level of CNTF-mRNA in differentiated or
resting state while they express high level of CNTF-mRNA 
upon transfer to culture or after injury. In this context, the high 
level of CNTF-mRNA in olfactory bulb in vivo could be a 
reflection of the presence of astrocytes around glomerulli acti- 
vated by the continuous degeneration f olfactory nerve. The 
remarkable difference between the CNTF-mRNA levels in the 
cultured cerebral cortex astrocytes and cerebral cortex in vivo 
could be explained accordingly. PACAP, VIP and other 
cAMP-linked agonists which are released from olfactory nerve 
or certain type of cells in olfactory bulb may convey the signal 
of olfactory nerve degeneration or regeneration upon astro- 
cytes to alter the CNTF and NGF expressions. In conclusion, 
we demonstrated the high level of CNTF expression in the 
cultured brain astrocytes and analyzed its cAMP-dependent 
regulatory mechanism which we hope applicable to the in vivo 
regulation of this unique neurotrophic factor in the olfactory 
system. 
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